+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Biologics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Biologics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082738
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Market grew from USD 430.59 billion in 2024 to USD 459.45 billion in 2025. It is expected to continue growing at a CAGR of 6.45%, reaching USD 626.76 billion by 2030.

Biologics have emerged as a pivotal pillar in modern therapeutics, offering targeted interventions for conditions ranging from oncology to autoimmune disorders. Recent advances in molecular engineering, cell culture techniques, and delivery systems have accelerated the translation of complex molecules into viable treatments. This introduction outlines the scope of this executive summary, highlighting the convergence of scientific innovation, regulatory evolution, and market dynamics that define the current biologics landscape. By examining transformative shifts, policy impacts, detailed segmentation, regional variations, and leading company strategies, this overview equips decision makers with a comprehensive foundation to inform strategic planning and investment decisions.

Transformative Shifts Reshaping the Biologics Sector

Over the past decade, breakthroughs in genetic editing and protein engineering have triggered a paradigm shift in biologics development. Precision modalities such as CAR-T cell therapies and gene editing platforms moved from experimental stages into approved treatments, fundamentally altering therapeutic approaches. Concurrently, flexible manufacturing innovations like modular bioprocessing and single-use technologies have reduced time-to-clinic, enabling faster scale-up and more efficient production. Regulatory agencies worldwide have responded by introducing adaptive pathways and accelerated approval schemes to accommodate these novel modalities. Collaboration between academic institutions, contract development and manufacturing organizations, and digital health providers has fostered an ecosystem where data analytics and artificial intelligence optimize candidate selection and formulation. These transformative shifts have not only enhanced the speed and precision of drug development but have also redefined competitive benchmarks, emphasizing agility, cross-disciplinary partnerships, and patient-centric design in the biologics sector.

Cumulative Impact of United States Tariffs in 2025

In 2025, new United States tariffs on selected active pharmaceutical ingredients and intermediate biologics components have introduced additional cost pressures across the supply chain. These levies affect raw materials sourced from key manufacturing hubs, compelling companies to reassess sourcing strategies and evaluate near-shoring alternatives. As import duties rise, margins on high-value products such as monoclonal antibodies and recombinant proteins face contraction unless offset by price adjustments or efficiency gains. To mitigate risk, industry players are investing in domestic manufacturing capacity, forging strategic alliances with local suppliers, and leveraging tariff-exempt free trade zones. While increased production costs pose near-term challenges, they also catalyze resilience through supply chain diversification. Over time, these adaptations may lead to strengthened regional ecosystems, though stakeholders must carefully manage inventory, negotiate long-term contracts, and monitor policy developments to maintain competitive positioning.

Key Segmentation Insights Across Multiple Dimensions

Detailed segmentation analysis reveals distinct performance and growth drivers across product, application, end-user, manufacturing process, technology, and disease indication dimensions. In product type, blood and blood products encompass plasma preparations, platelet preparations, and red blood cell preparations, addressing critical transfusion needs and emerging novel plasma-derived therapeutics. Cell therapy subdivides into allogeneic and autologous approaches, each presenting unique scalability and immunogenicity considerations. Gene therapy comprises ex vivo and in vivo modalities that target genetic disorders at the molecular level. Monoclonal antibodies include chimeric, human, humanized, and murine variants, driving targeted cancer and autoimmune treatments. Vaccine platforms span conjugate, inactivated, recombinant, and toxoid vaccines, underpinning both preventative and therapeutic immunization strategies.

Application segmentation encompasses autoimmune disorders such as multiple sclerosis and rheumatoid arthritis, cardiovascular diseases including atherosclerosis and myocardial infarction, infectious diseases with a focus on COVID-19 and hepatitis, neurological disorders targeting Alzheimer’s and Parkinson’s diseases, and oncology initiatives covering cancer vaccines, cell therapies, and antibody constructs. End-user analysis highlights biopharmaceutical companies split between large and small enterprises, diagnostic centers differentiated by pathology labs and radiology centers, hospitals and clinics composed of private clinics and public hospitals, and research organizations divided into academic and private research institutions.

Process-based segmentation examines upstream processing through cell culture and fermentation, formulation development in liquid and lyophilized forms, and downstream processing via purification and packaging. Technological categories include hybridoma technology involving fusions and monoclone selection, protein purification through chromatography and precipitation methods, and recombinant DNA technology spanning gene cloning and gene editing. Disease indication insights focus on endocrinology disorders such as diabetes and thyroid conditions alongside oncological diseases, with breast and lung cancer representing primary therapeutic targets. This multi-layered segmentation framework illuminates high-priority opportunities and nuanced challenges across the biologics ecosystem.

Key Regional Insights Informing Strategic Decisions

Regional dynamics demonstrate that the Americas maintain leadership through robust R&D infrastructure, deep venture capital pools, and advanced regulatory frameworks that facilitate accelerated approvals. The Europe, Middle East & Africa region leverages collaborative public-private partnerships, increasing investments in emerging biotech hubs while navigating complex reimbursement landscapes. Meanwhile, the Asia-Pacific zone experiences rapid capacity expansions driven by government incentives, cost-effective manufacturing ecosystems, and growing domestic demand for biologics. These regional variations influence strategic decisions on clinical trial localization, manufacturing footprint, and distribution networks, prompting companies to tailor market entry approaches to regulatory environments, patient demographics, and healthcare access patterns in each geography.

Key Company Insights Shaping Market Leadership

Industry leaders are deploying diverse strategies to reinforce their competitive edge. AbbVie Inc. and Amgen Inc. continue to pursue strategic alliances and in-licensing agreements to bolster their pipelines. AstraZeneca PLC and Bayer AG concentrate on integrating novel modalities into established therapeutic areas. Becton, Dickinson and Company and Biogen Inc. emphasize process optimization and automation to enhance throughput. BioPharm Laboratories, LLC and Bristol Myers Squibb Company invest in capacity expansions to address growing biologics demand. Catalent, Inc. and F. Hoffmann-La Roche Ltd. prioritize end-to-end service offerings, while Genentech, Inc. and Gilead Sciences, Inc. focus on next-generation antibody constructs and viral vector platforms. GlaxoSmithKline PLC and Innovent Biologics, Inc. target emerging markets with regionally adapted formulations. Johnson & Johnson Services, Inc. and Merck KGaA refine commercialization strategies for biosimilars and novel biologics. Novartis AG and Pfizer Inc. accelerate biosimilar launches through streamlined regulatory pathways. Sanofi S.A. and Thermo Fisher Scientific Inc. enhance support services for contract development and manufacturing, and Vertex Pharmaceuticals Inc. champions precision medicine approaches in rare disease portfolios.

Actionable Recommendations for Industry Leaders

To thrive in the evolving biologics ecosystem, industry leaders should prioritize a triad of strategies: accelerate innovation pipelines, fortify supply chain resilience, and deepen market access capabilities. First, channel R&D investments toward modular platforms that support agile candidate screening, including AI-driven discovery tools and high-throughput bioprocessing systems. Establish collaborative networks with academic centers and technology startups to co-develop next-generation modalities. Second, mitigate tariff and geopolitical risks by diversifying raw material sourcing, expanding regional manufacturing hubs, and optimizing inventory through digital supply chain platforms. Leverage predictive analytics to forecast disruptions and maintain buffer capacities. Third, refine commercial strategies by investing in value-based contracting, patient support programs, and real-world evidence generation to demonstrate clinical and economic outcomes. Customize market access frameworks for distinct regulatory and reimbursement environments, partnering with payers and healthcare systems to align on value metrics. By implementing these actionable steps, organizations can enhance operational agility, reduce time-to-market, and secure sustainable growth.

Conclusion: Navigating the Future of Biologics with Strategic Insight

The biologics sector stands at an inflection point where scientific breakthroughs converge with shifting policy landscapes and competitive imperatives. As transformational therapies progress from bench to bedside, stakeholders must balance the demands of innovation with practical considerations of cost, regulation, and market access. Integrating modular technology platforms, resilient supply chains, and value-oriented commercial models will be critical to sustaining momentum. By leveraging the insights presented herein-spanning segmentation, regional nuances, tariff impacts, and competitor strategies-decision makers can chart robust growth trajectories. Continued vigilance in monitoring emerging scientific trends, regulatory adaptations, and geopolitical developments will ensure that organizations remain at the forefront of this dynamic industry.

Market Segmentation & Coverage

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Blood And Blood Products
    • Plasma Preparations
    • Platelet Preparations
    • Red Blood Cell Preparations
  • Cell Therapy
    • Allogeneic Cell Therapy
    • Autologous Cell Therapy
  • Gene Therapy
    • Ex Vivo Gene Therapy
    • In Vivo Gene Therapy
  • Monoclonal Antibodies
    • Chimeric Monoclonal Antibodies
    • Human Monoclonal Antibodies
    • Humanized Monoclonal Antibodies
    • Murine Monoclonal Antibodies
  • Vaccines
    • Conjugate Vaccines
    • Inactivated Vaccines
    • Recombinant Vaccines
    • Toxoid Vaccines
  • Autoimmune Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
  • Cardiovascular Diseases
    • Atherosclerosis
    • Myocardial Infarction
  • Infectious Diseases
    • COVID-19
    • Hepatitis
  • Neurological Disorders
    • Alzheimer’s Disease
    • Parkinson’s Disease
  • Oncology
    • Cancer Vaccines
    • Cell Therapies
    • Monoclonal Antibodies
  • Biopharmaceutical Companies
    • Large Biopharma Enterprises
    • Small Biopharma Enterprises
  • Diagnostic Centers
    • Pathology Labs
    • Radiology Centers
  • Hospitals And Clinics
    • Private Clinics
    • Public Hospitals
  • Research Organizations
    • Academic Research
    • Private Research
  • Downstream Processing
    • Packaging
    • Purification
  • Formulation Development
    • Liquid Formulation
    • Lyophilized Formulation
  • Upstream Processing
    • Cell Culture
    • Fermentation
  • Hybridoma Technology
    • Fusions
    • Monoclone Selection
  • Protein Purification
    • Chromatography Methods
    • Precipitation Methods
  • Recombinant DNA Technology
    • Gene Cloning
    • Gene Editing
  • Endocrinology Disorders
    • Diabetes
    • Thyroid Disorders
  • Oncological Diseases
    • Breast Cancer
    • Lung Cancer

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biologics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen Inc.
  • BioPharm Laboratories, LLC
  • Bristol Myers Squibb Company
  • Catalent, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics Market, by Product Type
8.1. Introduction
8.2. Blood And Blood Products
8.2.1. Plasma Preparations
8.2.2. Platelet Preparations
8.2.3. Red Blood Cell Preparations
8.3. Cell Therapy
8.3.1. Allogeneic Cell Therapy
8.3.2. Autologous Cell Therapy
8.4. Gene Therapy
8.4.1. Ex Vivo Gene Therapy
8.4.2. In Vivo Gene Therapy
8.5. Monoclonal Antibodies
8.5.1. Chimeric Monoclonal Antibodies
8.5.2. Human Monoclonal Antibodies
8.5.3. Humanized Monoclonal Antibodies
8.5.4. Murine Monoclonal Antibodies
8.6. Vaccines
8.6.1. Conjugate Vaccines
8.6.2. Inactivated Vaccines
8.6.3. Recombinant Vaccines
8.6.4. Toxoid Vaccines
9. Biologics Market, by Application
9.1. Introduction
9.2. Autoimmune Disorders
9.2.1. Multiple Sclerosis
9.2.2. Rheumatoid Arthritis
9.3. Cardiovascular Diseases
9.3.1. Atherosclerosis
9.3.2. Myocardial Infarction
9.4. Infectious Diseases
9.4.1. COVID-19
9.4.2. Hepatitis
9.5. Neurological Disorders
9.5.1. Alzheimer’s Disease
9.5.2. Parkinson’s Disease
9.6. Oncology
9.6.1. Cancer Vaccines
9.6.2. Cell Therapies
9.6.3. Monoclonal Antibodies
10. Biologics Market, by End User
10.1. Introduction
10.2. Biopharmaceutical Companies
10.2.1. Large Biopharma Enterprises
10.2.2. Small Biopharma Enterprises
10.3. Diagnostic Centers
10.3.1. Pathology Labs
10.3.2. Radiology Centers
10.4. Hospitals And Clinics
10.4.1. Private Clinics
10.4.2. Public Hospitals
10.5. Research Organizations
10.5.1. Academic Research
10.5.2. Private Research
11. Biologics Market, by Manufacturing Process
11.1. Introduction
11.2. Downstream Processing
11.2.1. Packaging
11.2.2. Purification
11.3. Formulation Development
11.3.1. Liquid Formulation
11.3.2. Lyophilized Formulation
11.4. Upstream Processing
11.4.1. Cell Culture
11.4.2. Fermentation
12. Biologics Market, by Technology
12.1. Introduction
12.2. Hybridoma Technology
12.2.1. Fusions
12.2.2. Monoclone Selection
12.3. Protein Purification
12.3.1. Chromatography Methods
12.3.2. Precipitation Methods
12.4. Recombinant DNA Technology
12.4.1. Gene Cloning
12.4.2. Gene Editing
13. Biologics Market, by Disease Indication
13.1. Introduction
13.2. Endocrinology Disorders
13.2.1. Diabetes
13.2.2. Thyroid Disorders
13.3. Oncological Diseases
13.3.1. Breast Cancer
13.3.2. Lung Cancer
14. Americas Biologics Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Biologics Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Biologics Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Amgen Inc.
17.3.3. AstraZeneca PLC
17.3.4. Bayer AG
17.3.5. Becton, Dickinson and Company
17.3.6. Biogen Inc.
17.3.7. BioPharm Laboratories, LLC
17.3.8. Bristol Myers Squibb Company
17.3.9. Catalent, Inc.
17.3.10. F. Hoffmann-La Roche Ltd.
17.3.11. Genentech, Inc.
17.3.12. Gilead Sciences, Inc.
17.3.13. GlaxoSmithKline PLC
17.3.14. Innovent Biologics, Inc.
17.3.15. Johnson & Johnson Services, Inc.
17.3.16. Merck KGaA
17.3.17. Novartis AG
17.3.18. Pfizer Inc.
17.3.19. Sanofi S.A.
17.3.20. Thermo Fisher Scientific Inc.
17.3.21. Vertex Pharmaceuticals Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BIOLOGICS MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PLASMA PREPARATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY PLATELET PREPARATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY RED BLOOD CELL PREPARATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY CHIMERIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY HUMAN MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY MURINE MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY LARGE BIOPHARMA ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY SMALL BIOPHARMA ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY RADIOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOLOGICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY PRIVATE RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOLOGICS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BIOLOGICS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BIOLOGICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BIOLOGICS MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL BIOLOGICS MARKET SIZE, BY FUSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONE SELECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL BIOLOGICS MARKET SIZE, BY CHROMATOGRAPHY METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL BIOLOGICS MARKET SIZE, BY PRECIPITATION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL BIOLOGICS MARKET SIZE, BY GENE CLONING, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL BIOLOGICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL BIOLOGICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 105. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 132. AMERICAS BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 133. AMERICAS BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 134. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 191. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. CANADA BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 193. CANADA BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 194. CANADA BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 195. CANADA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 196. CANADA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 197. CANADA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. CANADA BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 199. CANADA BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 200. CANADA BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 201. CANADA BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. CANADA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 203. CANADA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. CANADA BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 205. CANADA BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 206. CANADA BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 207. CANADA BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 208. CANADA BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 209. CANADA BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 210. CANADA BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 211. CANADA BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 212. CANADA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. CANADA BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. CANADA BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 215. CANADA BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. CANADA BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 217. CANADA BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 218. CANADA BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 219. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. MEXICO BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 221. MEXICO BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 222. MEXICO BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 223. MEXICO BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 224. MEXICO BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 225. MEXICO BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. MEXICO BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. MEXICO BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 228. MEXICO BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 229. MEXICO BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 230. MEXICO BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 231. MEXICO BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. MEXICO BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 233. MEXICO BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 234. MEXICO BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 235. MEXICO BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 236. MEXICO BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 237. MEXICO BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 238. MEXICO BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 239. MEXICO BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 240. MEXICO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. MEXICO BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 242. MEXICO BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 243. MEXICO BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 244. MEXICO BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 245. MEXICO BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 246. MEXICO BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 247. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. UNITED STATES BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 249. UNITED STATES BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 250. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 251. UNITED STATES BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 252. UNITED STATES BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 253. UNITED STATES BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. UNITED STATES BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. UNITED STATES BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 256. UNITED STATES BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 257. UNITED STATES BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 258. UNITED STATES BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 259. UNITED STATES BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. UNITED STATES BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 261. UNITED STATES BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 262. UNITED STATES BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 263. UNITED STATES BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 264. UNITED STATES BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 265. UNITED STATES BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 266. UNITED STATES BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 267. UNITED STATES BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 268. UNITED STATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. UNITED STATES BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. UNITED STATES BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 271. UNITED STATES BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. UNITED STATES BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 273. UNITED STATES BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 274. UNITED STATES BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 275. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 280. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 282. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 284. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 285. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 287. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 288. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 290. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 291. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 292. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 311. AUSTRALIA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. AUSTRALIA BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 313. AUSTRALIA BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 314. AUSTRALIA BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 315. AUSTRALIA BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 316. AUSTRALIA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 317. AUSTRALIA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. AUSTRALIA BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 319. AUSTRALIA BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 320. AUSTRALIA BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 321. AUSTRALIA BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 322. AUSTRALIA BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 323. AUSTRALIA BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 324. AUSTRALIA BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 325. AUSTRALIA BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 326. AUSTRALIA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 327. AUSTRALIA BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 328. AUSTRALIA BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 329. AUSTRALIA BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA BIOLOGICS MARKET SIZE, BY ONCOLOGICAL DISEASES, 2018-2030 (USD MILLION)
TABLE 333. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 334. CHINA BIOLOGICS MARKET SIZE, BY BLOOD AND BLOOD PRODUCTS, 2018-2030 (USD MILLION)
TABLE 335. CHINA BIOLOGICS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 336. CHINA BIOLOGICS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 337. CHINA BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 338. CHINA BIOLOGICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 339. CHINA BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 340. CHINA BIOLOGICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 341. CHINA BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 342. CHINA BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 343. CHINA BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 344. CHINA BIOLOGICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 345. CHINA BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 346. CHINA BIOLOGICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 347. CHINA BIOLOGICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 348. CHINA BIOLOGICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 349. CHINA BIOLOGICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 350. CHINA BIOLOGICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 351. CHINA BIOLOGICS MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 352. CHINA BIOLOGICS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 353. CHINA BIOLOGICS MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 354. CHINA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 355. CHINA BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 356. CHINA BIOLOGICS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2030 (USD MILLION)
TABLE 357. CHINA BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 358. CHINA BIOLOGICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 359. CHINA BIOLOGICS MARKET SIZE, BY ENDOCRINOLOGY DISORDERS, 2018-2

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen Inc.
  • BioPharm Laboratories, LLC
  • Bristol Myers Squibb Company
  • Catalent, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biologics & Biosimilars CXO Services Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Biologics & Biosimilars CXO Services Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global, United States Global, United States
From
Biologics Contract Manufacturing Market by Product, Platform, Therapeutic Area, Scale of Operation - Global Forecast 2025-2030 - Product Image

Biologics Contract Manufacturing Market by Product, Platform, Therapeutic Area, Scale of Operation - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Biologics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biologics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.